Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Return on Equity (2016 - 2025)

CytomX Therapeutics' Return on Equity history spans 11 years, with the latest figure at 0.17% for Q4 2025.

  • For Q4 2025, Return on Equity rose 250.0% year-over-year to 0.17%; the TTM value through Dec 2025 reached 0.17%, up 250.0%, while the annual FY2025 figure was 0.35%, 98.0% up from the prior year.
  • Return on Equity reached 0.17% in Q4 2025 per CTMX's latest filing, down from 0.25% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 8.25% in Q1 2022 to a low of 7.73% in Q4 2021.
  • Average Return on Equity over 5 years is 0.09%, with a median of 0.08% recorded in 2023.
  • Peak YoY movement for Return on Equity: soared 1093bps in 2022, then crashed -743bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 7.73% in 2021, then skyrocketed by 115bps to 1.19% in 2022, then plummeted by -99bps to 0.01% in 2023, then crashed by -23219bps to 2.67% in 2024, then skyrocketed by 94bps to 0.17% in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Return on Equity are 0.17% (Q4 2025), 0.25% (Q3 2025), and 0.66% (Q2 2025).